Bio Plus Co

Bio Plus Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Bio Plus Co (099430.KQ) as of Nov 20, 2026 is 98.25 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 157.51 % — a change of -37.63% (lower).

Cash Conversion

98.25 %

YoY

-37.63%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Bio Plus Co is 2025 98.25 % . Cash Conversion Rate (OCF/Net Income) of Bio Plus Co was 2024 157.51 % . It decreases by -37.63% lower compared to the previous year.

The Bio Plus Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
135.31 KRW
Jan 1, 2019
88.27 KRW
Jan 1, 2020
103.51 KRW
Jan 1, 2021
125.10 KRW
Jan 1, 2022
63.20 KRW
Jan 1, 2023
62.71 KRW
Jan 1, 2024
157.51 KRW
Jan 1, 2025
98.25 KRW
The Bio Plus Co Cash Conversion history
YEARCash ConversionYoY
98.25 %-37.63%
157.51 %+151.20%
62.71 %-0.79%
63.20 %-49.48%
125.10 %+20.87%
103.51 %+17.26%
88.27 %-34.77%
135.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Cash Conversion Rate (OCF/Net Income) of Bio Plus Co is 98.25 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Bio Plus Co changed from 157.51 % to 98.25 %, representing a -37.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Bio Plus Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Plus Co

All Key Metrics — Bio Plus Co